InvestWiser
Xbrane Biopharma AB
XBRANE · Nasdaq Stockholm · Healthcare
10.40SEK
−1.4%last day
Price as of 2 October 2026
Performance
1 month
+4.0%
1 year
−68.1%
3 years, per year
−70.1%
5 years, per year
−64.8%
Largest fall, 3 years
−99.6%
Below the peak now
−99.6%
Volatility, 1 year
93.9%
Return with dividends reinvested.
Key figures
P/E
negative earnings
P/B
0.4
Dividend yield
0.0%
Return on equity
−13.8%
Net margin
−89.3%
Market value
21 m USD
Quality, value and trend
Where Xbrane Biopharma stands against every Nordic stock today. 100 is best.
71
Profitability and a sound balance sheet over time. Better than 71% of Nordic stocks.
47
The price measured against earnings, assets and cash flow. Better than 47% of Nordic stocks.
45
The price development over the past year. Better than 45% of Nordic stocks.
54
Quality, value and trend together. Better than 54% of Nordic stocks.
About Xbrane Biopharma
Xbrane Biopharma AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 29 employees.
Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. It offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults.
See the full analysis in InvestWiser.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
See the full analysis